Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Lung Cancer. 2010 Jan 29;70(1):37–42. doi: 10.1016/j.lungcan.2010.01.004

Figure 4. 50 mg/kg gefitinib, in addition to PGIS overexpression, significantly decreases tumor multiplicity.

Figure 4

PGIS overexpressors treated with gefitinib 50 mg/kg thrice weekly show decreased tumor multiplicity, while a dose of 100 mg/kg did not alter tumor development. All PGIS overexpressors had lower tumor multiplicity and volume compared to wildtype mice, as previously described.